Paper20008845
Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.
Toole BP. Clin Cancer Res, 2009. Cited by 295 papers, by iCite.
Cite this record
ConductScience Library. Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Papers, record 20008845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20008845
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA073839 | NCI NIH HHS | United States | R01CA073839 | PubMed and NIH | NIH RePORTER |
| R01 CA082867 | NCI NIH HHS | United States | R01CA082867 | PubMed and NIH | NIH RePORTER |
References68
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2680347 | Clinical uses of hyaluronan. | Ciba Found Symp | 1989 | https://conductscience.org/library/papers/2680347 | PubMed |
| 2 | 18691086 | The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs. | Curr Pharm Biotechnol | 2008 | https://conductscience.org/library/papers/18691086 | PubMed |
| 3 | 18566232 | DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18566232 | PubMed |
| 4 | 14762695 | CD44v6: a target for antibody-based cancer therapy. | Cancer Immunol Immunother | 2004 | https://conductscience.org/library/papers/14762695 | PubMed |
| 5 | 18547053 | Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. | Mol Pharm | 2008 | https://conductscience.org/library/papers/18547053 | PubMed |
| 6 | 17591972 | Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. | Am J Pathol | 2007 | https://conductscience.org/library/papers/17591972 | PubMed |
| 7 | 19279714 | Engineering a clinically-useful matrix for cell therapy. | Organogenesis | 2008 | https://conductscience.org/library/papers/19279714 | PubMed |
| 8 | 18450474 | Altered hyaluronan biosynthesis in cancer progression. | Semin Cancer Biol | 2008 | https://conductscience.org/library/papers/18450474 | PubMed |
| 9 | 9839618 | Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. | Cancer Lett | 1998 | https://conductscience.org/library/papers/9839618 | PubMed |
| 10 | 10871609 | Hyaluronan binding by cell surface CD44. | J Biol Chem | 2000 | https://conductscience.org/library/papers/10871609 | PubMed |
| 11 | 17465836 | The role of hyaluronic acid in hemopoietic stem cell biology. | Regen Med | 2006 | https://conductscience.org/library/papers/17465836 | PubMed |
| 12 | 19060478 | A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. | Chemotherapy | 2009 | https://conductscience.org/library/papers/19060478 | PubMed |
| 13 | 17416541 | Alternative splicing in cancer: noise, functional, or systematic? | Int J Biochem Cell Biol | 2007 | https://conductscience.org/library/papers/17416541 | PubMed |
| 14 | 17683255 | Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. | Expert Opin Drug Deliv | 2007 | https://conductscience.org/library/papers/17683255 | PubMed |
| 15 | 16061646 | The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/16061646 | PubMed |
| 16 | 16998484 | Targeting of CD44 eradicates human acute myeloid leukemic stem cells. | Nat Med | 2006 | https://conductscience.org/library/papers/16998484 | PubMed |
| 17 | 18349857 | Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? | Nat Clin Pract Oncol | 2008 | https://conductscience.org/library/papers/18349857 | PubMed |
| 18 | 18490190 | Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. | Drug Resist Updat | 2008 | https://conductscience.org/library/papers/18490190 | PubMed |
| 19 | 19594639 | Immunological functions of hyaluronan and its receptors in the lymphatics. | Immunol Rev | 2009 | https://conductscience.org/library/papers/19594639 | PubMed |
| 20 | 16998483 | Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. | Nat Med | 2006 | https://conductscience.org/library/papers/16998483 | PubMed |
Cited by177
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 295 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42822349 | IGF2BP1 regulates chicken skeletal muscle development through an m6A-dependent inter-organ regulatory axis. | Poult Sci | 2026 | https://conductscience.org/library/papers/42822349 | PubMed |
| 42797312 | Evaluation of Histidine-Octamer-Modified Hyaluronic Acid as a Cytosolic Drug Delivery Material via CD44-Mediated Cellular Uptake and Endosomal Escape. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797312 | PubMed |
| 42675095 | Nanoparticle-enhanced apigenin suppresses androgen receptor signaling and cellular plasticity in LNCaP cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/42675095 | PubMed |
| 42509832 | Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities. | Biomolecules | 2026 | https://conductscience.org/library/papers/42509832 | PubMed |
| 42453152 | Selective magnetic particle imaging of CD44 expressing cells using iron oxide nanoprobes functionalized with chemically modified hyaluronan. | Nanoscale Adv | 2026 | https://conductscience.org/library/papers/42453152 | PubMed |
| 42447444 | Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42447444 | PubMed |
| 42144617 | Multitargeted nanoparticles inhibit cancer invasion by disrupting cancer-associated fibroblast-tumor cell crosstalk and modulating collagen pattern and EMT. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42144617 | PubMed |
| 41155434 | Hyaluronic Acid in Liver Fibrosis: Role in Inflammation, Tissue Remodeling, and Disease Progression. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41155434 | PubMed |
| 40881990 | Molecular flexibility of hyaluronic acid has a profound effect on invasion of cancer cells. | R Soc Open Sci | 2025 | https://conductscience.org/library/papers/40881990 | PubMed |
| 40806330 | Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806330 | PubMed |
| 39594665 | Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. | Cells | 2024 | https://conductscience.org/library/papers/39594665 | PubMed |
| 39239513 | Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis. | Theranostics | 2024 | https://conductscience.org/library/papers/39239513 | PubMed |
| 38981928 | Investigation of the Circular Transcriptome in Alzheimer's Disease Brain. | J Mol Neurosci | 2024 | https://conductscience.org/library/papers/38981928 | PubMed |
| 38672650 | CD44: A New Prognostic Marker in Colorectal Cancer? | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38672650 | PubMed |
| 38542115 | Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542115 | PubMed |
| 38169677 | Biomaterial-assisted local oxygenation safeguards the prostimulatory phenotype and functions of human dendritic cells in hypoxia. | Front Immunol | 2023 | https://conductscience.org/library/papers/38169677 | PubMed |
| 38089093 | Engineered In Vitro Tumor Model Recapitulates Molecular Signatures of Invasion in Glioblastoma. | ACS Mater Au | 2023 | https://conductscience.org/library/papers/38089093 | PubMed |
| 38026520 | Endogenous H2O2 Self-Replenishment and Sustainable Cascades Enhance the Efficacy of Sonodynamic Therapy. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/38026520 | PubMed |
| 37958796 | The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37958796 | PubMed |
| 37761989 | Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37761989 | PubMed |
Genes23
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20008845
GET https://conductscience.org/api/papers/v1/20008845/references?page=2